JP2009519935A5 - - Google Patents

Download PDF

Info

Publication number
JP2009519935A5
JP2009519935A5 JP2008545740A JP2008545740A JP2009519935A5 JP 2009519935 A5 JP2009519935 A5 JP 2009519935A5 JP 2008545740 A JP2008545740 A JP 2008545740A JP 2008545740 A JP2008545740 A JP 2008545740A JP 2009519935 A5 JP2009519935 A5 JP 2009519935A5
Authority
JP
Japan
Prior art keywords
volume
mass
aqueous pharmaceutical
pharmaceutical suspension
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008545740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009519935A (ja
JP5308824B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/047393 external-priority patent/WO2007070517A2/en
Publication of JP2009519935A publication Critical patent/JP2009519935A/ja
Publication of JP2009519935A5 publication Critical patent/JP2009519935A5/ja
Application granted granted Critical
Publication of JP5308824B2 publication Critical patent/JP5308824B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008545740A 2005-12-14 2006-12-12 フェキソフェナジン懸濁液製剤 Expired - Fee Related JP5308824B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75030305P 2005-12-14 2005-12-14
US60/750,303 2005-12-14
PCT/US2006/047393 WO2007070517A2 (en) 2005-12-14 2006-12-12 Fexofenadine suspension formulation

Publications (3)

Publication Number Publication Date
JP2009519935A JP2009519935A (ja) 2009-05-21
JP2009519935A5 true JP2009519935A5 (OSRAM) 2010-01-21
JP5308824B2 JP5308824B2 (ja) 2013-10-09

Family

ID=38120312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008545740A Expired - Fee Related JP5308824B2 (ja) 2005-12-14 2006-12-12 フェキソフェナジン懸濁液製剤

Country Status (38)

Country Link
US (1) US8933097B2 (OSRAM)
EP (1) EP1965768B1 (OSRAM)
JP (1) JP5308824B2 (OSRAM)
KR (1) KR101452792B1 (OSRAM)
CN (1) CN101316580B (OSRAM)
AR (1) AR058323A1 (OSRAM)
AT (1) ATE431137T1 (OSRAM)
AU (1) AU2006326551B2 (OSRAM)
BR (1) BRPI0619895B1 (OSRAM)
CA (1) CA2633086C (OSRAM)
CR (1) CR9993A (OSRAM)
CY (1) CY1109320T1 (OSRAM)
DE (1) DE602006006870D1 (OSRAM)
DK (1) DK1965768T3 (OSRAM)
DO (1) DOP2006000274A (OSRAM)
EC (1) ECSP088532A (OSRAM)
EG (1) EG25866A (OSRAM)
ES (1) ES2327168T3 (OSRAM)
HN (1) HN2008000875A (OSRAM)
HR (1) HRP20090411T1 (OSRAM)
IL (1) IL192067A (OSRAM)
JO (1) JO2549B1 (OSRAM)
MA (1) MA30152B1 (OSRAM)
MY (1) MY146988A (OSRAM)
NO (1) NO339877B1 (OSRAM)
NZ (1) NZ568943A (OSRAM)
PE (1) PE20071003A1 (OSRAM)
PL (1) PL1965768T3 (OSRAM)
PT (1) PT1965768E (OSRAM)
RS (1) RS51135B (OSRAM)
RU (1) RU2405538C2 (OSRAM)
SI (1) SI1965768T1 (OSRAM)
TN (1) TNSN08186A1 (OSRAM)
TW (1) TWI377061B (OSRAM)
UA (1) UA89584C2 (OSRAM)
UY (1) UY30021A1 (OSRAM)
WO (1) WO2007070517A2 (OSRAM)
ZA (1) ZA200803985B (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101546774B1 (ko) 2008-07-29 2015-08-24 엘지전자 주식회사 휴대 단말기 및 그 동작제어 방법
WO2013058996A1 (en) 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
JP6410814B2 (ja) 2013-07-01 2018-10-24 アベンティスユービー・エルエルシー フェキソフェナジンを含む経口投与用液体医薬組成物
CN105358138A (zh) * 2013-07-03 2016-02-24 R.P.谢勒技术有限公司 包含非索非那定的胶囊制剂
CN103610645B (zh) * 2013-11-25 2016-05-11 浙江万晟药业有限公司 一种非索非那定盐酸盐的药物组合物及制备方法
CN106806346B (zh) * 2015-12-01 2020-09-11 国药集团广东环球制药有限公司 一种非索非那定盐酸盐干混悬剂制剂及其制备方法
CN109906079B (zh) * 2016-06-16 2022-09-30 库蒂斯制药公司 用于质子泵抑制剂混悬剂的组合物和方法
JP7169671B2 (ja) 2017-06-02 2022-11-11 テイカ製薬株式会社 難水溶性成分可溶化ミセル及びそれを含有する液剤
US11633478B2 (en) 2019-07-16 2023-04-25 Azurity Pharmaceuticals, Inc. Compositions and kits for Omeprazole suspension
US10751333B1 (en) 2019-07-16 2020-08-25 Cutispharma, Inc. Compositions and kits for omeprazole suspension
WO2022038474A1 (en) * 2020-08-18 2022-02-24 Innate S.R.L. Injectable composition and use of said composition
WO2022175829A1 (en) 2021-02-17 2022-08-25 Cellix Bio Private Limited Topical formulations and compositions
US20250082623A1 (en) * 2021-12-29 2025-03-13 Opella Healthcare Group Sas Compositions containing fexofenadine
CN115715759B (zh) * 2022-11-03 2024-01-12 京海盛达(北京)科技有限公司 一种抗组胺混悬剂及其制备方法
CR20240566A (es) * 2023-01-20 2025-02-25 Opella Healthcare Group Sas Formulaciones de fexofenadina sin parabenos
WO2026074306A1 (en) 2024-10-03 2026-04-09 Opella Healthcare Group Sas Chewable fexofenadine tablets

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4254129A (en) 1979-04-10 1981-03-03 Richardson-Merrell Inc. Piperidine derivatives
US4829064A (en) 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
CA2449419C (en) 1994-05-18 2011-09-06 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US6132758A (en) 1998-06-01 2000-10-17 Schering Corporation Stabilized antihistamine syrup
US6319513B1 (en) * 1998-08-24 2001-11-20 The Procter & Gamble Company Oral liquid mucoadhesive compounds
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
US20060083691A1 (en) * 2000-05-10 2006-04-20 Wermeling Daniel P Intranasal opioid compositions, delivery devices and methods of using same
DE60225694T2 (de) 2001-07-31 2008-06-26 Texcontor Etablissement Neues polymorph von fexo-fenadin
US6723348B2 (en) * 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
EP1587496B1 (en) * 2003-01-30 2009-10-07 Ethypharm Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles
US20050250737A1 (en) * 2003-11-12 2005-11-10 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
DK2486942T3 (en) * 2004-11-24 2019-01-28 Meda Pharmaceuticals Inc COMPOSITIONS CONTAINING AZELASTINE AND PROCEDURES FOR USING IT
AU2006278874A1 (en) 2005-07-27 2007-02-15 Sandoz Ag A process for the preparation of substituted phenyl ether compounds and rosiglitazone
JP5133244B2 (ja) * 2005-08-05 2013-01-30 ルピン・リミテッド フェキソフェナジンの経口用医薬懸濁組成物

Similar Documents

Publication Publication Date Title
CA2633086A1 (en) Fexofenadine suspension formulation
KR20150011807A (ko) 자일리톨계 항-점액성 조성물과 관련 방법 및 조성물
NZ208127A (en) Pharmaceutical compositions containing ranitidine
BRPI0718541A2 (pt) Preparação líquida compreendendo um complexo de pimobendan e ciclodextrina
WO2016159897A1 (en) Potassium citrate suspension
KR20100087002A (ko) 발사르탄을 포함하는 액체 조성물
JP2590156B2 (ja) 経口投与用医薬組成物
US20150034087A1 (en) Low Dose Pharmaceutical Composition Comprising Zanamivir
CN102078285A (zh) 含有皮质激素和h1受体拮抗剂的鼻用原位凝胶
JP4580921B2 (ja) 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む医薬組成物
JP2022527630A5 (OSRAM)
JP2009516001A (ja) リポキシゲナーゼ阻害剤とシクロデキストリンとを含む組成物
CN102362855B (zh) 一种伊曲康唑异构体口服溶液
CN102078612A (zh) 含有糠酸莫米松和h1受体拮抗剂的鼻用原位凝胶
CN102933198B (zh) 包含曲普坦化合物的制剂
TH92487A (th) การตั้งสูตรยาน้ำแขวนตะกอนของฟีโซฟีนาดีน
WO2022007743A1 (zh) 粘膜给药剂型和其应用
JP2014037377A (ja) 医薬製剤およびその製造方法
JP3364453B2 (ja) センノシド含有水性液剤
JP5311825B2 (ja) 2−イミダゾリン構造を有するα−交感神経興奮薬の新規な使用
JP4275394B2 (ja) 注射用シロスタゾール水性製剤
WO2004000320A1 (ja) 水性点眼用製剤
CA2361882A1 (en) Liquid for oral administration comprising paroxetine
RU2010132368A (ru) Пероральные фармацевтические суспензии, содержащие парацетамол и ибупрофен
KR20160067175A (ko) 안정한 경구 투여용 트리플루살 분말 제형 및 이의 제조방법